Ipamorelin: research reference

Distinguish local mechanism from integrated effect. A whole-axis result needs its time context and cannot be summarized by a receptor name.

GHSR-1a is a Gq protein-coupled receptor whose activation mobilizes intracellular calcium. In cellular models, the peptide shows selectivity for this target over other related receptors.

The purity value is a product-label specification, not an assay result. A batch result can only be asserted from that batch’s certificate.

These names help identify the catalog entry. A descriptive label is not evidence of efficacy, and structural identity still requires appropriate documentation.

GH secretagogue

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Personal protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

The foundational 1998 paper used rat pituitary cells in vitro, anesthetized rats and conscious pigs. It measured growth-hormone release alongside GHRP-6 and GHRP-2 and used GHRP and GHRH antagonists to locate signaling at the secretagogue receptor. In pigs, FSH, LH, prolactin and TSH did not change; ACTH and cortisol changed with GHRP-6 and GHRP-2 but not with ipamorelin.

A separate longitudinal bone-growth experiment used adult female rats for fifteen days, intravital tetracycline labeling and distances between fluorescent bands in the proximal tibial metaphysis. Total IGF-I, IGF-binding proteins, serum bone-turnover markers and multinucleated TRAP-positive cells did not change. Longitudinal growth rate and body-weight gain did change.

The bibliography includes a multicenter, randomized, double-blind, placebo-controlled phase 2 study in 117 adults following bowel resection. Its primary endpoint, time to tolerance of a standardized solid meal, did not differ significantly from placebo. A 2026 narrative review reports greater maximum tetanic tension with a CJC-1295 combination in mouse glucocorticoid-induced muscle-loss models; that finding remains animal evidence. Sources: PMID 9849822; PMID 10373343; PMID 25331030; PMID 41476424.

Exposure information comes from one 1999 modeling study with five ascending infusion rates and eight healthy participants per level. It describes a short terminal half-life on the order of two hours, with clearance and steady-state distribution volume described as proportional over the examined range. Growth-hormone release occurred as one episode, peaking before the first hour and then declining exponentially, fitted with an indirect-response population model. Between-person variability was greater in response parameters than exposure parameters.

The references do not describe albumin binding, the specific enzymatic degradation pathway or reconstituted-material stability. Information on peptidase resistance is compositional rather than measured: the declared sequence includes three noncanonical residues—Aib, D-2-Nal and D-Phe—and an amidated carboxyl terminus. Sources: PMID 10496658; PMID 9849822.

Ipamorelin is not a fragment cut from a human protein. The 1998 paper places it in a chemical series constructed by removing the central Ala-Trp dipeptide from GHRP-1 and selecting this compound for its selectivity profile. The paper came from Novo Nordisk’s growth-hormone biology department in Måløv, Denmark. NNC 26-0161 is its development code.

Its publication title—describing the first selective growth-hormone secretagogue—summarized the claimed animal finding: among then-known GHRP receptor agonists, growth-hormone-release selectivity comparable to GHRH itself. The chronology runs from pharmacological characterization in 1998 to healthy-participant exposure-response modeling in 1999 and a 2014 gastrointestinal proof-of-concept study describing it as a ghrelin mimetic. No reference here describes phase 3. Sources: PMID 9849822; PMID 10496658; PMID 25331030.

Ipamorelin is the catalog’s only GH secretagogue. Nearby references share a category rather than a class: CJC-1295 No-DAC and CJC-1295 DAC are GHRH analogs, and the Ipamorelin + CJC-1295 No-DAC blend combines those classes.

The difference is target identity, not degree. The literature locates binding at the ghrelin/secretagogue receptor using antagonists that exclude the GHRH receptor occupied by a GHRH analog. Structure also differs: five residues, three noncanonical, versus the 29 residues of GHRH(1–29).

The foundational paper compared ipamorelin with GHRP-6 and GHRP-2, not GHRH analogs. Those two are absent from the catalog. ACTH and cortisol behavior, rather than the magnitude of growth-hormone release, distinguished it in those animal studies. Sources: PMID 9849822; PMID 41476424.

The controlled postoperative study found no significant difference from placebo in primary or secondary endpoints and described its sample as small and heterogeneous. No phase 3 study appears here. Clinical-outcome evidence does not extend beyond that hospital postoperative setting; the separate healthy-volunteer publication concerns exposure-response modeling.

In the bone model, fifteen days of repeated exposure did not alter total IGF-I or binding proteins, despite the usual assumption that pituitary signaling translates into circulating IGF-I. The same paper described a somewhat reduced pituitary response by day fifteen, with no longer follow-up in these references.

The two 2026 reviews agree that the evidence is predominantly animal—one places two-thirds of retrieved publications in preclinical animal models—and that human studies are few and weakly controlled. Sources: PMID 25331030; PMID 10373343; PMID 41476424; PMID 42578445.